Medical Supply Chain Resiliency Act
- Sponsor
- Rep. Malliotakis, Nicole [R-NY-11]
- Committees
- Rules Committee (primary)
- Last action
- Mar 18, 2025
Bottom line
This bill empowers the President to forge new trade alliances to secure the U.S. medical supply chain, with significant congressional checks and balances.
What it actually does
This bill authorizes the President to negotiate and enter into trade agreements with "trusted trade partners" for the reciprocal elimination of duties and other import restrictions on medical goods. These agreements aim to enhance U.S. national security and public health by diversifying medical supply chains, promoting regulatory cooperation, and protecting intellectual property, particularly in response to lessons learned from the COVID-19 pandemic. The bill establishes detailed criteria for selecting partners, outlines potential provisions for such agreements, and mandates extensive congressional oversight and review.
Proponents argue
Supporters argue this bill is a proactive measure to prevent future medical supply shortages and reduce reliance on potentially unreliable foreign sources, thereby bolstering national security and public health. They emphasize the importance of diversifying supply chains and fostering collaboration with trusted allies to ensure access to critical medical goods during emergencies.
Opponents contend
Critics might argue that granting the President broad authority to eliminate duties could lead to job losses in domestic medical manufacturing if not carefully managed, or that it could inadvertently weaken existing trade protections. Some might also express concern about the potential for these agreements to be used for purposes beyond strict medical supply chain resilience, or that the definition of "trusted trade partner" might be too broad or too narrow.
The bill is relatively concise for its scope, allowing an informed reader to grasp its core mechanisms within a reasonable timeframe.
Section 1
Short Title: Medical Supply Chain Resiliency Act
This section establishes the official short name for the Act as the "Medical Supply Chain Resiliency Act." This title clearly communicates the bill's primary focus on strengthening the nation's medical supply chains.
Supporters argue
Proponents argue that a clear and concise short title is standard legislative practice, making the bill easily identifiable and its purpose immediately understandable to the public and other stakeholders.
Critics contend
No specific opposition is typically raised against this provision, as it is a procedural element common to all legislation.
Tradeoffs
None.
Section 2
Congressional Findings and Sense of Congress on Supply Chain Vulnerabilities
This section details the vulnerabilities of the U.S. medical supply chain exposed by the COVID-19 pandemic, including over-reliance on a few foreign partners and the impact of foreign export restrictions. It expresses Congress's view that diversifying trade relationships with reliable partners is critical for national security and public health, setting the foundational rationale for the bill's actions.
Section 5(a)
Authorization for President to Enter into Trusted Trade Partner Agreements
This provision grants the President the authority to negotiate, enter into, and enforce trade agreements with countries for the reciprocal elimination of duties or other import restrictions on medical goods. This authority is contingent on the President determining such agreements contribute to U.S. national security and public health. The President can also proclaim modifications to duties to carry out these agreements.
Section 5(b)
Criteria for Selecting Trusted Trade Partners
This section outlines seven specific considerations the President must take into account when determining whether to negotiate with a country for a trusted trade partner agreement. These criteria include the country's expressed desire for an agreement, commitment to open trade during public health emergencies, adherence to existing free trade agreements, measures to reduce trade barriers, maintenance of the rule of law, adequate intellectual property protection, and agreement to promote good regulatory practices.
Section 5(c)
Permissible Provisions in Trusted Trade Partner Agreements
This section specifies ten types of provisions that may be included in these trusted trade partner agreements. These range from duty reduction and diversification of supplier networks to harmonization of regulatory procedures, increased access to government procurement markets, intellectual property protection, collaboration frameworks for research and development, and exemption from trade-restrictive measures during public health emergencies.
Section 6
Congressional Oversight and Disapproval Process
This section establishes a robust framework for congressional oversight of the President's authority to enter into trusted trade partner agreements. It includes requirements for 60-day notice before negotiations, mandatory consultations with relevant committees and federal agencies, detailed reports to Congress before proclaiming duty actions and before entering agreements, and a congressional review period (up to 120 days) during which a joint resolution of disapproval can prevent an agreement from taking effect.
Section 7
Monitoring and Enforcement of Continued Compliance
This section directs the Trade Representative to periodically monitor compliance by trusted trade partners with their agreement commitments. If a partner fails to comply, the Trade Representative reports to the President, who then determines whether to suspend or withdraw the agreement, seek compensatory trade benefits, or take other actions, including suspending the partner's exemption from trade-restrictive measures during a public health emergency. A 15-day timeline is set for implementing presidential action.
The definition of "medical good" includes "any medical device, pharmaceutical good, or input for such a device or good."
Section 4(4)
Why it matters:This is standard legislative practice to define terms upfront for clarity and consistency throughout the bill.
Case for: Supporters argue that including "inputs" ensures comprehensive coverage of the entire medical supply chain, addressing vulnerabilities at every stage from raw materials to finished products, which is essential for true resilience.
Case against: Critics might suggest that such a broad definition could lead to overly complex negotiations, covering a vast array of products and materials, potentially slowing down the agreement process.
Estimated impact: Significantly expands the scope of potential trade agreements beyond finished medical products to include critical components and raw materials, enhancing the bill's ability to address upstream supply chain vulnerabilities.
Trusted trade partner agreements may include a provision to exempt parties from U.S. trade-restrictive measures imposed with respect to medical goods during a public health emergency. Conversely, the President can suspend this exemption as an enforcement action if a partner fails to comply with the agreement.
Sections 5(c)(10) and 7(2)(B)(iii)
Why it matters:It is part of a comprehensive list of potential agreement terms and enforcement tools, not necessarily an attempt to hide it.
Case for: Proponents argue this provides a strong incentive for countries to become trusted partners, ensuring critical supplies can flow freely during crises without being hampered by U.S. restrictions, and offers a powerful enforcement lever.
Case against: Critics might view this as potentially tying the U.S.'s hands in future emergency responses, or that suspending such an exemption could be a politically difficult action to take, even in cases of non-compliance.
Estimated impact: Could significantly alter trade flows and access to medical goods during future pandemics by pre-emptively removing trade barriers for trusted partners, and provides a key tool for ensuring partner adherence.